Day One Announces Topline Data from Pivotal Phase 2 FIREFLY-1 Trial Demonstrating Meaningful Responses with Tovorafenib (DAY101) in Recurrent or Progressive Pediatric Low-Grade Glioma
January 08, 2023 17:00 ET
|
Day One Biopharmaceuticals, Inc.
Overall response rate (ORR) of 64% and clinical benefit rate (CBR) of 91% in 69 heavily-pretreated, RANO-evaluable patientsMedian duration of 8.4 months on therapy as of September 28, 2022, with 77%...
Day One to Present at the 41st Annual J.P. Morgan Healthcare Conference
December 20, 2022 08:00 ET
|
Day One Biopharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing...
Day One to Participate in the Piper Sandler 34th Annual Healthcare Conference
November 17, 2022 07:00 ET
|
Day One Biopharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing...
Day One Announces Upcoming Presentations at 2022 Society for Neuro-Oncology Annual Meeting
November 11, 2022 07:00 ET
|
Day One Biopharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 11, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing...
Day One Reports Third Quarter 2022 Financial Results and Corporate Progress
November 07, 2022 16:30 ET
|
Day One Biopharmaceuticals, Inc.
Topline results for full pivotal FIREFLY-1 study population with tovorafenib (DAY101) in relapsed or progressive pediatric low-grade glioma (pLGG) are expected in the first quarter of 2023 ...
Day One Announces Cooperative Research and Development Agreement with National Cancer Institute to Expand Development of Tovorafenib (DAY101)
October 17, 2022 08:00 ET
|
Day One Biopharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing...
Day One Appoints Garry Nicholson as Chairman of the Board of Directors
September 12, 2022 08:30 ET
|
Day One Biopharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing...
Day One Reports Second Quarter 2022 Financial Results and Corporate Progress
August 04, 2022 16:30 ET
|
Day One Biopharmaceuticals, Inc.
Reported positive initial data from ongoing pivotal FIREFLY-1 study with tovorafenib (DAY101) in relapsed pediatric low-grade glioma (pLGG); topline results for full pivotal study population expected...
Day One to Participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference
August 02, 2022 08:00 ET
|
Day One Biopharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing...
Day One Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
June 21, 2022 08:30 ET
|
Day One Biopharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., June 21, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing...